Drug Profile
Tralokinumab companion diagnostic - Abbott
Latest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 07 Aug 2017 Phase III development is ongoing in Asia, Canada, European Union and USA
- 13 May 2015 Phase-III clinical trials in Asthma (Diagnosis) in Asia, Canada, European Union and USA (unspecified route)